ArticleJournal of neuro-oncology2025
Assessment of outcomes and machine Learning-based models to predict local failure risk following stereotactic radiosurgery for small brain metastases.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe assessed the outcomes of stereotactic radiosurgery (SRS) for small intact brain metastases (SBM) (≤ 2 cm) and developed machine learning (ML) algorithms to predict the probability of local failure (LF).
methodsConsecutive patients with SBM treated with SRS between January 2017 and July 2022 were included. Propensity score matching (PSM) was performed with related factors to enhance balance for comparison. Variable selection and three time-varied generalized estimating equations (GEE) were used to create predictive models.
results1503 SBMs in 235 patients treated over 358 SRS courses were analyzable. The actuarial 1-year cumulative rate of LF was lower in lesions treated with 24 Gy (5.9%, 95% CI: 4.2-8.2%) or 22 Gy (7.7%, 95% CI: 5.3-11.0%) compared to 20 Gy (25.3%, 95% CI: 18.1-34.7%) (p < 0.001). 22 Gy and 24 Gy were associated with a 63% and 74% reduction in risk in LF compared to 20 Gy (HR: 0.37; 95% CI: 0.24-0.57; p < 0.005 and HR: 0.26; 95% CI: 0.17-0.39; p < 0.005, respectively). The generated models could recommend the best dose with an individualized percentage probability of LF with each dose at 6 months, 1 year, and 2 years with a minimum AUC of 0.75. The 1-year model had the highest AUC (0.88), accuracy (88%), and specificity (91%), while the 2-year model had the highest sensitivity (89%).
conclusionThe ML models developed predict LF as a function of dose which could aid in clinical decision-making to select an appropriate dose for SBM to optimize tumor control outcomes and schedule appropriate follow-up.
Indexed as
Identifiers
40512282What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.